Stéphane Oudard

65.7k total citations · 13 hit papers
618 papers, 38.8k citations indexed

About

Stéphane Oudard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Stéphane Oudard has authored 618 papers receiving a total of 38.8k indexed citations (citations by other indexed papers that have themselves been cited), including 471 papers in Pulmonary and Respiratory Medicine, 275 papers in Oncology and 181 papers in Cancer Research. Recurrent topics in Stéphane Oudard's work include Renal cell carcinoma treatment (228 papers), Prostate Cancer Treatment and Research (218 papers) and Renal and related cancers (103 papers). Stéphane Oudard is often cited by papers focused on Renal cell carcinoma treatment (228 papers), Prostate Cancer Treatment and Research (218 papers) and Renal and related cancers (103 papers). Stéphane Oudard collaborates with scholars based in France, United States and United Kingdom. Stéphane Oudard's co-authors include Thomas E. Hutson, Sylvie Négrier, Ronald M. Bukowski, Robert J. Motzer, Cezary Szczylik, Bernard Escudier, Robert A. Figlin, Piotr Tomczak, M. Dror Michaelson and Christine Théodore and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Stéphane Oudard

586 papers receiving 38.1k citations

Hit Papers

Sunitinib versus Interfer... 2004 2026 2011 2018 2007 2004 2007 2010 2008 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
    2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. profile →
  2. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
    2004 4.3k citations Stéphane Oudard et al. profile →
  3. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
    2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
  4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    2010 2.4k citations Stéphane Oudard et al. profile →
  5. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. profile →
  6. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
  7. Phase 3 trial of everolimus for metastatic renal cell carcinoma
    2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
  8. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
    2018 868 citations Fred Saad, Stéphane Oudard et al. profile →
  9. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
    2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
  10. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
  11. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
    2015 356 citations Nicolás A. Giraldo, Étienne Becht et al. Clinical Cancer Research profile →
  12. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
    2015 315 citations Frédéric Rolland, Stéphane Oudard et al. European Urology profile →
  13. Bone health in cancer: ESMO Clinical Practice Guidelines
    2020 294 citations Stéphane Oudard et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stéphane Oudard 27.5k 16.5k 13.8k 12.0k 4.9k 618 38.8k
José Baselga 14.1k 0.5× 19.7k 1.2× 25.8k 1.9× 9.8k 0.8× 6.3k 1.3× 484 46.7k
Bernard Escudier 26.8k 1.0× 22.9k 1.4× 14.5k 1.0× 14.0k 1.2× 1.8k 0.4× 717 41.8k
Robert A. Figlin 25.4k 0.9× 22.0k 1.3× 12.1k 0.9× 12.1k 1.0× 1.7k 0.3× 470 38.0k
Eric J. Small 24.2k 0.9× 8.9k 0.5× 14.3k 1.0× 8.3k 0.7× 6.7k 1.4× 613 35.7k
Karim Fizazi 25.3k 0.9× 6.5k 0.4× 14.8k 1.1× 8.0k 0.7× 9.9k 2.0× 835 36.7k
Fred Saad 23.9k 0.9× 7.6k 0.5× 15.4k 1.1× 6.9k 0.6× 8.7k 1.8× 1.2k 36.7k
Ronald M. Bukowski 19.9k 0.7× 17.7k 1.1× 13.4k 1.0× 10.3k 0.9× 1.4k 0.3× 459 34.0k
Walter M. Stadler 14.1k 0.5× 11.9k 0.7× 9.4k 0.7× 7.2k 0.6× 2.3k 0.5× 473 26.8k
Brian I. Rini 25.8k 0.9× 19.7k 1.2× 15.6k 1.1× 12.9k 1.1× 1.3k 0.3× 769 38.4k
Pasi A. Jänne 40.7k 1.5× 25.7k 1.6× 35.9k 2.6× 13.6k 1.1× 3.7k 0.8× 653 61.5k

Countries citing papers authored by Stéphane Oudard

Since Specialization
Citations

This map shows the geographic impact of Stéphane Oudard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Oudard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Oudard more than expected).

Fields of papers citing papers by Stéphane Oudard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Oudard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Oudard. The network helps show where Stéphane Oudard may publish in the future.

Co-authorship network of co-authors of Stéphane Oudard

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Oudard. A scholar is included among the top collaborators of Stéphane Oudard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Oudard. Stéphane Oudard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Auclin, Édouard, Clément Dumont, H. Gauthier, et al.. (2026). Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer. 24(2). 102506–102506.
2.
Benhamouda, Nadine, et al.. (2025). The CD70–CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target. Clinical Cancer Research. 31(14). 2872–2881. 2 indexed citations
3.
Gervais, Claire, et al.. (2024). Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report. European Annals of Otorhinolaryngology Head and Neck Diseases. 141(4). 231–234.
4.
Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2024). CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 18–18. 20 indexed citations
5.
Oudard, Stéphane, Pierre Combe, Ali Hasbini, et al.. (2024). ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.. Journal of Clinical Oncology. 42(16_suppl). TPS5127–TPS5127. 1 indexed citations
6.
Else, Tobias, Eric Jonasch, Othon Iliopoulos, et al.. (2024). Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clinical Cancer Research. 30(9). 1750–1757. 11 indexed citations
7.
Oudard, Stéphane, Laura K. Aguilar, Lorena Lupinacci, et al.. (2023). OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC. Journal of Thoracic Oncology. 18(11). S80–S80. 1 indexed citations
8.
Narayan, Vivek, Othon Iliopoulos, Benjamin L. Maughan, et al.. (2023). SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY. Neuro-Oncology Advances. 5(Supplement_3). iii31–iii31. 1 indexed citations
9.
Powles, Thomas, Zoe J. Assaf, Viraj Degaonkar, et al.. (2023). Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. 85(2). 114–122. 61 indexed citations
10.
Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2018). Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology. 36(8). 765–772. 121 indexed citations
11.
Verbiest, Annelies, Diether Lambrechts, Thomas Van Brussel, et al.. (2018). Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer. 16(4). 266–273. 8 indexed citations
12.
Giraldo, Nicolás A., Étienne Becht, Yann Vano, et al.. (2017). Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 23(15). 4416–4428. 263 indexed citations
13.
Bernichtein, Sophie, Natascha Pigat, Nicolas Barry Delongchamps, et al.. (2016). Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. Cancer Research. 77(2). 355–365. 42 indexed citations
14.
Granier, Clémence, Charles Dariane, Pierre Combe, et al.. (2016). Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Research. 77(5). 1075–1082. 163 indexed citations
15.
Giraldo, Nicolás A., Étienne Becht, Franck Pagès, et al.. (2015). Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research. 21(13). 3031–3040. 356 indexed citations breakdown →
16.
Beuselinck, Benoit, Sylvie Job, Étienne Becht, et al.. (2015). Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. Clinical Cancer Research. 21(6). 1329–1339. 230 indexed citations
17.
Remark, Romain, Marco Alifano, Isabelle Cremer, et al.. (2013). Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. Clinical Cancer Research. 19(15). 4079–4091. 284 indexed citations
18.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(22). 3584–3590. 1711 indexed citations breakdown →
19.
Escudier, Bernard, Tim Eisen, Walter M. Stadler, et al.. (2009). Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology. 27(20). 3312–3318. 864 indexed citations breakdown →
20.
Choueiri, Toni K., A. Plantade, Paul Elson, et al.. (2007). Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. Journal of Clinical Oncology. 26(1). 127–131. 311 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by Bernard Escudier Breakdown of academic impact, for papers by Robert A. Figlin Breakdown of academic impact, for papers by Eric J. Small Breakdown of academic impact, for papers by Karim Fizazi Breakdown of academic impact, for papers by Fred Saad Breakdown of academic impact, for papers by Ronald M. Bukowski Breakdown of academic impact, for papers by Walter M. Stadler Breakdown of academic impact, for papers by Brian I. Rini Breakdown of academic impact, for papers by Pasi A. Jänne
Rankless by CCL
2026